Cohort 3
Cohort 3 is an intervention with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
4 of 4 finished
0.0%
0 ended early
2
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Identification and Description of Patients With High-risk Non Metastatic RCC
CD22 Redirected Autologous T Cells for ALL
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Phase I Study of Safety and Immunogenicity of ADU-623
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical Trials (6)
Identification and Description of Patients With High-risk Non Metastatic RCC
CD22 Redirected Autologous T Cells for ALL
A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Phase I Study of Safety and Immunogenicity of ADU-623
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
All 6 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 6